Skip to main content
. 2021 Feb 5;11:598118. doi: 10.3389/fgene.2020.598118

FIGURE 5.

FIGURE 5

Analysis on data from GSE80667, described in Fertig et al. (2016). HaCaT premalignant keratinocyte cell line (mock), with overexpressed wild-type EGFR (EGFR),or activating mutation in HRAS (HRASV12D) (HRAS) or PIK3CA (PIK3CAH1047R) (PIK3CA) genes; treated for 24 h with cetuximab, gefitinib, or afatinib. Measured FOXO activity score per analyzed sample, presented on a log2odds scale; PI3K pathway activity is the inverse of the FOXO activity score.